ESR1 and breast carcinoma: In addition to inhibiting the growth of cancer cells, a study by Zimmermann et al. revealed that metformin demonstrated a synergistic effect when combined with fulvestrant, an estrogen receptor antagonist, in ER-positive breast cancer cells [234].